ArticleMedicine2025
Causal association of blood metabolites, immune cells, and lung cancer: A mediation Mendelian randomization study.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mendelian randomization analysis unveils causal associations between immune cells, metabolites, and lung cancer risk.Discover oncology · 2025Article
- Mendelian randomization analyses support causal relationships between unswitched memory B cells and lung squamous cell carcinoma.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Lung cancer ranks highest in annual mortality among all cancers, and blood metabolites may influence its onset and progression. Our objective is to assess the causal relationships between blood metabolites and both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), while exploring the mediating effects of immune cells. We utilized publicly available genetic data to investigate the potential causal relationships between blood metabolites and NSCLC as well as SCLC using a 2-sample Mendelian randomization (MR) approach. In our primary analysis, we employed the inverse variance weighted (IVW) method and conducted sensitivity analyses and Steiger test to assess the reliability and directionality of the causal relationships. Additionally, we employed a 2-step MR approach to evaluate the mediating role of immune cells in these causal relationships. The IVW method revealed that palmitoylcarnitine levels (metabolon platform) and 4 other blood metabolites are risk factors for NSCLC, while tetrahydrocortisol glucuronide levels and 2 other blood metabolites are protective factors for NSCLC. Additionally, Alpha-hydroxyisovalerate levels and 8 other blood metabolites are risk factors for SCLC, whereas dimethylglycine levels and 3 other blood metabolites are protective factors for SCLC. Furthermore, IgD- CD27- B cell %B cell, CD27 on IgD- CD38dim B cell, and CD3 on Naive CD4+ T cell mediate some of the relationships between blood metabolites and NSCLC. Activated and secreting CD4 regulatory T cell %CD4+ T cell, CD14- CD16- Absolute Count, and IgD on IgD+ CD24+ B cell mediate some of the relationships between blood metabolites and SCLC. There are significant causal relationships between blood metabolites and both NSCLC and SCLC, with some of these relationships mediated by immune cells. This aids us in influencing the role of blood metabolites in lung cancer by intervening with immune cells, thereby providing more avenues for the prevention and treatment of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.